PROSTATE-SPECIFIC ANTIGEN TESTING IN UNTREATED AND TREATED PROSTATIC ADENOCARCINOMA

被引:44
作者
RAINWATER, LM
MORGAN, WR
KLEE, GG
ZINCKE, H
机构
[1] MAYO CLIN & MAYO FDN,DEPT UROL,ROCHESTER,MN 55905
[2] MAYO CLIN & MAYO FDN,CLIN CHEM SECT,ROCHESTER,MN 55905
关键词
D O I
10.1016/S0025-6196(12)62725-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The isolation and purification of prostate-specific antigen (PSA) and the development of a radioimmunoassay for this antigen represent major advancements for the detection of adenocarcinoma of the prostate and the monitoring of response to therapy in patients with this disease. Both monoclonal and polyclonal assays for PSA are available. In attempts to correlate pathologic tumor stage and PSA levels, tumors of higher stage (pathologic stages C1, C2, D1, and D2) have been associated with elevated PSA levels. Increased PSA levels have also been found in patients with benign prostatic diseases (benign prostatic hypertrophy and prostatitis). PSA has been shown to be an excellent marker after radical prostatectomy and for monitoring of radiation therapy. Patients with a persistently elevated PSA level for more than 6 months postoperatively should be assessed for residual or recurrent local or systemic disease. Thus far, routine use of PSA testing as a mass screening modality for prostatic cancer has not been considered cost-effective. © 1990, Mayo Foundation for Medical Education and Research. All rights reserved.
引用
收藏
页码:1118 / 1126
页数:9
相关论文
共 58 条
  • [31] Morote J, 1986, Int J Biol Markers, V1, P141
  • [32] NATIV O, IN PRESS J UROL
  • [33] NOWELS K, 1988, ARCH PATHOL LAB MED, V112, P734
  • [34] PROSTATE SPECIFIC ANTIGEN IN THE PREOPERATIVE AND POSTOPERATIVE EVALUATION OF LOCALIZED PROSTATIC-CANCER TREATED WITH RADICAL PROSTATECTOMY
    OESTERLING, JE
    CHAN, DW
    EPSTEIN, JI
    KIMBALL, AW
    BRUZEK, DJ
    ROCK, RC
    BRENDLER, CB
    WALSH, PC
    [J]. JOURNAL OF UROLOGY, 1988, 139 (04) : 766 - 772
  • [35] PROSTATE SPECIFIC ANTIGEN IN THE STAGING OF LOCALIZED PROSTATE-CANCER - INFLUENCE OF TUMOR DIFFERENTIATION, TUMOR VOLUME AND BENIGN HYPERPLASIA
    PARTIN, AW
    CARTER, HB
    CHAN, DW
    EPSTEIN, JI
    OESTERLING, JE
    ROCK, RC
    WEBER, JP
    WALSH, PC
    [J]. JOURNAL OF UROLOGY, 1990, 143 (04) : 747 - 752
  • [36] ALTERATIONS IN SERUM LACTATE DEHYDROGENASE AND ITS 4TH AND 5TH ISOZYMES IN PATIENTS WITH PROSTATIC CARCINOMA
    PROUT, GR
    MACALALAG, EV
    DENIS, LJ
    PRESTON, LW
    [J]. JOURNAL OF UROLOGY, 1965, 94 (04) : 451 - +
  • [37] PURNELL DM, 1984, CANCER RES, V44, P285
  • [38] ROBLES JM, 1988, EUR UROL, V14, P360
  • [39] EVALUATION OF PROSTATE-SPECIFIC ANTIGEN AND PROSTATIC ACID-PHOSPHATASE AS PROSTATE-CANCER MARKERS
    SEAMONDS, B
    YANG, N
    ANDERSON, K
    WHITAKER, B
    SHAW, LM
    BOLLINGER, JR
    [J]. UROLOGY, 1986, 28 (06) : 472 - 479
  • [40] SIDDALL JK, 1986, CLIN CHEM, V32, P2040